PE0116 + PE0105

PE0116 + PE0105 is an investigational combination therapy being evaluated for the treatment of advanced solid tumors. The combination is currently in Phase 1b/2 clinical trials to assess its safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The trial includes dose escalation and expansion phases to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). According to available information, both agents are administered as intravenous injections. At least one component of the combination (PE0116) is described as a recombinant human anti-PD-1 monoclonal antibody, suggesting an immunotherapy mechanism targeting immune checkpoint pathways. The developer of this drug combination is Shanghai HyaMab Biotechnology.